Peptide research

Wolverine peptide stack: reading a "tested together" claim

Wolverine peptide stack claims often say the two peptides were tested together. Before accepting that, a reader can ask four questions of the paper behind it. The answers decide what the result can support.

The Wolverine peptide stack research page applies these questions to the two records that include BPC-157 and TB-500 in one study. The Wolverine peptide guide page explains the name.

Which groups did the study have?

A claim about a pair needs a group that received the pair and a group for each peptide alone, plus an untreated comparison. The 2026 rat Achilles tendon paper has exactly that layout: control, BPC-157, TB-500 and combination, eight rats each. Source: 2026 BPC-157 and TB-500 rat study, PMID 42542926. With only a combination group, a paper could not say whether the pair did anything the parts did not.

Which material did the authors test?

FDA's July 2026 TB-500 briefing calls TB-500 a common name and says it has seen multiple salts and derivatives sold under it. Source: FDA briefing document on TB-500. A paper that says TB-500 may therefore describe the fragment or something else. The rat paper's abstract calls its material synthetic thymosin beta-4 (TB-500) without settling that point.

Which model produced the result?

The rat paper measured a repaired Achilles tendon in rats after four weeks. A different model, such as cultured cells or a person's knee, would answer a different question. The 2011 BPC-157 paper used rat tendon cells in culture. Source: 2011 BPC-157 rat tendon-cell study, PMID 21030672.

Was there a comparison at all?

The 2021 chart review counted how many of 16 patients reported improvement. Its abstract describes no comparison group, so the counts cannot separate a treatment effect from recovery over time. Source: 2021 knee-pain chart review, PMID 34324435.

What does the search find?

On October 15, 2026, a ClinicalTrials.gov search for BPC-157 and TB-500 together returned no record. Source: dated ClinicalTrials.gov search.

A listing, a lot report and a paper each document something different. The Curo recovery catalog listing for BPC-157 + TB-500 shows what one seller states about the pair. Curo's lot-certificate library and Curo's testing-method page describe the report fields for a lot.

Sources checked October 15, 2026. Reference information for laboratory research.

BPC-157: what FDA's 2026 briefing document covers, section by section

BPC-157 has a long paper trail in animal studies and a short one in people. FDA's briefing document for its July 2026 advisory committee, dated May 11, 2026, reviews that record in detail. This post walks through its sections and says what each one covers. Why FDA

TB-500 Peptide: Matching a Listing Name to FDA, PubChem and WADA Records

TB-500 peptide listings rarely agree on what the name covers. This note walks through the public records that tie the name to a specific molecule and shows what each record confirms. The TB-500 peptide guide gives the same material question by question. Step 1: the sequence The reference

Retatrutide: reading the weight-loss number in a trial paper

Retatrutide trial headlines usually give one weight-loss figure, and the same trial can yield two figures. Five questions help place any figure: which analysis produced it, who was in the trial, how long it ran, whether a journal has published it and which material it describes. The retatrutide trials

Tesamorelin peptide: what an FDA label does and does not tell you about a vial

Tesamorelin peptide is unusual among research compounds because a finished prescription drug made from it has an FDA label. Three documents get mixed up here: the label for the finished product, a supplier's listing for a vial, and a lot report for one lot. Each one records its